DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells
about
The Role of Invariant Natural Killer T Cells in Dendritic Cell Licensing, Cross-Priming, and Memory CD8(+) T Cell GenerationRole of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune responseToll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγUnique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine.DNA is an efficient booster of dendritic cell-based vaccineBoosting the Immune Response: The Use of iNKT cell ligands as vaccine adjuvantsCombination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine.New Approaches to Immunotherapy for HPV Associated Cancers.DNA vaccines: roles against diseases.Optimizing NKT cell ligands as vaccine adjuvantsRecent progress in vaccination against human papillomavirus-mediated cervical cancer.Chronic hepatitis B surface antigen seroclearance-related immune factors.Glycolipid activators of invariant NKT cells as vaccine adjuvants.Induction of hepatitis B virus surface antigen-specific cytotoxic T lymphocytes can be up-regulated by the inhibition of indoleamine 2, 3-dioxygenase activity.De-oncogenic HPV E6/E7 vaccine gets enhanced antigenicity and promotes tumoricidal synergy with cisplatin.Antibody production by in vivo RNA transfection.Natural Killer T Cells in Cancer ImmunotherapyActivities of stromal and immune cells in HPV-related cancers.
P2860
Q26797344-8DEC0B1B-846D-4E17-A61C-11EDA6DC382AQ26996330-6E4B0209-8A5D-414D-B6BD-D579B640DE2DQ34438411-DE761D73-D89A-4854-8F5B-D7D800F5D5F0Q36103115-E20CB893-A08C-489C-9FFB-9250F5CFE107Q36256389-A078E142-8C3D-46E4-BC4D-F7F486358C85Q36474450-6467763A-2FD7-4328-B129-C1B1D5999B0BQ36503451-29B99E94-A63F-49D0-96A9-2CEA1A2CF159Q37137430-AEE65FF9-B9E3-46BF-A410-B3C19B9DFB40Q37441566-5F6231B9-DFBF-4451-81F6-D069D1FD007BQ38206819-95F28A66-0FBD-44BA-91FF-54049BA17832Q38370782-351D319D-81AC-407B-8A9E-8042A589F295Q38809744-F05BAA46-0037-4355-B249-3606D41A9FCFQ38885794-004A80C2-A3A5-46AA-8CA0-DE8FF90C8F92Q39020028-FC09418C-469B-4BC6-8314-CB3F08F11BC5Q39062363-86E0B2EB-56AA-4E11-A1C8-D738054C7E02Q40052131-91686B7C-FF4D-45A2-B1B5-C13125F8B620Q42078314-E4ADC3F2-8AF3-497A-B009-DC1818804B9FQ55507801-5ED112F1-87B7-4C21-964D-4B3EA0A01983
P2860
DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
DNA vaccine with α-galactosylc ...... gen-expressing dendritic cells
@ast
DNA vaccine with α-galactosylc ...... gen-expressing dendritic cells
@en
type
label
DNA vaccine with α-galactosylc ...... gen-expressing dendritic cells
@ast
DNA vaccine with α-galactosylc ...... gen-expressing dendritic cells
@en
prefLabel
DNA vaccine with α-galactosylc ...... gen-expressing dendritic cells
@ast
DNA vaccine with α-galactosylc ...... gen-expressing dendritic cells
@en
P2093
P2860
P1433
P1476
DNA vaccine with α-galactosylc ...... gen-expressing dendritic cells
@en
P2093
Chien-Fu Hung
Daejin Kim
Yeong-Min Park
P2860
P304
P356
10.1016/J.VACCINE.2010.08.079
P407
P577
2010-09-17T00:00:00Z